KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2016 - 2025)

Alnylam Pharmaceuticals' Long-Term Investments history spans 17 years, with the latest figure at $22.2 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 67.68% year-over-year to $22.2 million; the TTM value through Dec 2025 reached $22.2 million, down 67.68%, while the annual FY2025 figure was $22.2 million, 67.68% down from the prior year.
  • Long-Term Investments reached $22.2 million in Q4 2025 per ALNY's latest filing, down from $51.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $68.6 million in Q4 2024 to a low of $22.2 million in Q4 2025.
  • Average Long-Term Investments over 5 years is $49.8 million, with a median of $49.4 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: soared 65.38% in 2021, then plummeted 67.68% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $40.9 million in 2021, then rose by 20.78% to $49.4 million in 2022, then rose by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then tumbled by 67.68% to $22.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Long-Term Investments are $22.2 million (Q4 2025), $51.3 million (Q3 2025), and $68.6 million (Q2 2025).